Retatrutide vs Orforglipron
Compare the research profiles of Retatrutide and Orforglipron. Read the individual guides for evidence and limitations.
How to interpret this comparison
This page summarizes database profiles and has not yet received a study-by-study editorial review. Use the linked guides and primary sources to evaluate a specific claim.
How to read peptide studiesRetatrutide
Retatrutide (LY3437943)
Category
weight-loss
Research Level
Phase 3 Clinical Trials
FDA Status
clinical-trials
Orforglipron
Orforglipron (LY3502970)
Category
weight-loss
Research Level
Phase 3 Clinical Trials
FDA Status
clinical-trials
Detailed Comparison
| Aspect | Retatrutide | Orforglipron |
|---|---|---|
| Overview | A triple hormone receptor agonist (GLP-1/GIP/Glucagon) in clinical trials by Eli Lilly. Shows remarkable weight loss results up to 29% body weight. Often misleadingly called "GLP-3" on gray market.... | The most anticipated upcoming weight loss drug - the first oral non-peptide GLP-1 receptor agonist. Unlike current oral options, it does not require fasting before consumption, potentially removing a ... |
| Research topics (not established benefits) |
|
|
| Side Effects |
|
|
| Mechanism | Activates three receptors simultaneously: GLP-1, GIP, and glucagon. The glucagon component may provide additional metabolic benefits and fat burning.... | Small molecule that activates GLP-1 receptors orally without the peptide structure. Provides similar effects to injectable GLP-1s but in pill form.... |
Frequently Asked Questions
Does a comparison establish which treatment is better?
Only appropriately designed evidence for the same clinical question can support that conclusion. Database categories and mechanisms alone cannot rank treatments.
Does this page establish that these compounds can be combined?
No. This page does not assess interactions or the benefit and safety of combined use. Individual studies cannot establish the effects of a combination.